Biotest Aktiengesellschaft (FRA:BIO)

Market Cap	1.40B
Revenue (ttm)	635.20M
Net Income (ttm)	-24.50M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	0.04 (0.09%)
Ex-Dividend Date	Jul 3, 2025

Volume	n/a
Average Volume	263
Open	42.20
Previous Close	42.20
Day's Range	42.20 - 42.20
52-Week Range	40.40 - 43.20
Beta	n/a
RSI	41.44
Earnings Date	Aug 4, 2025

About FRA:BIO

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immun...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1946
• Employees: 2,495
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BIO

Financial Performance

In 2024, FRA:BIO's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.